MedTrace Logo

Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial

NCT04883671 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-09-23

No results posted yet for this study

Summary

The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival.

The name(s) of the study intervention involved in this study is:

* Stereotactic Body Radiation Therapy (SBRT)

Conditions

  • Adenoid Cystic Carcinoma
  • Metastatic Adenoid Cystic Carcinoma

Interventions

OTHER

Standard of Care

Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).

RADIATION

SBRT

SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer

Sponsors & Collaborators

  • Adenoid Cystic Carcinoma Research Foundation

    collaborator OTHER

  • Gateway for Cancer Research

    collaborator OTHER

  • Dana-Farber Cancer Institute

    lead OTHER

Principal Investigators

  • Jonathan D Schoenfeld, MD, MPH · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-27
Primary Completion
2028-06-01
Completion
2030-06-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04883671 on ClinicalTrials.gov